Leukemia, Myelodysplasia, Transplantation
News
FDA Approves Chemotherapeutic Enzyme L-Asparaginase
News
JAK Inhibitor Ruxolitinib Wins First FDA Approval in Myelofibrosis
News
Geriatric Assessment Predicts Overall Survival in AML
Major Finding: Scores of less than 9 out of 12 on the Short Physical Performance Battery (SPPB) and less than 77 out of 100 on a Modified Mini-...
News
Making Inroads in Treatment of Adult ALL
News
Transplant Protocol Benefits Elderly With Hematologic Cancers
Major Finding: The 5-year survival was 35% overall and as high as 69% in the lowest-risk patients among those aged 60-75 years whose advanced...
News
Refined Risk Stratification Guides Leukemia Transplant Decisions
News
Ambulatory Encounters for Hematology/Oncology Unchanged Since 2007
News
FDA: Increased PAH Risk Seen With Dasatinib
Article
Personalized medicine: myth to reality
News
CD19-redirected T cells induce remission in CLL patients
News
Brd4: Potential new target in AML
“The drug candidate not only displays remarkable anti-leukemia activity in aggressive disease models and against cells derived from patients with...